SOURCE: Cerora, Inc.

Cerora, Inc.

April 28, 2014 08:09 ET

Cerora Debuts Qumpass™ Online Neuropsychological Testing Software Suite Today at the American Academy of Neurology Meeting

Data From Qumpass™ Can Help Neurologists Treating Kids' Concussions Make More Informed "Return-to-Learn" Decisions

BETHLEHEM, PA--(Marketwired - Apr 28, 2014) - Cerora, Inc., a StartUp Health / GE Healthcare Entrepreneurship program and Ben Franklin Technology Partners of Northeastern Pennsylvania company, announces the debut today at its commercial exhibit booth #1605 at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia of its new Qumpass™ neuropsychological testing software -- directly aimed at providing neurologists and other physicians with data to empower more informed "Return-to-Learn" decisions when treating kids with concussions or head-injuries.

"The AAN meeting is providing a very important opportunity for Cerora to present and discuss our clinical data with the world's leading neurologists," commented Dr. Adam Simon, Cerora CEO and new member to AAN. "We are particularly pleased that the debut of our Qumpass software is taking place against the backdrop of the three important Cerora clinical studies that are being presented as part of the meeting's scientific program."

"I've been very impressed with the Cerora Qumpass software ever since implementing it in my clinical office practice," noted Stephen J. Martino, MD, Scientific Advisory Board member to Cerora and AAN member. "I suspect the Qumpass software will one day become the new standard of care in treating concussed patients and be a part of every practicing neurologist's office."

Qumpass is Cerora's first commercial product and initial step in an expanding solution for brain health assessment. It will be followed by additional hardware and software products that will include Cerora's proprietary MindReader™ brainwave sensing technology -- designed to enable professionals to gather truly objective data, which, along with neuropsychological performance data, self-reporting of symptoms, and additional biosensor-based measures, can lead to more accurate clinical determinations.

Objective data -- provided rapidly, near the athletic field in the case of concussion -- would offer a considerable advantage over current assessments which are typically based solely on subjective clinical impressions.

About Cerora
Cerora is leading the way in the development and testing of software and hardware technologies required to provide critically important, objective, portable biomarker-based brain-function diagnostic information. Located at the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania's TechVentures on Lehigh University's Mountaintop Campus in Bethlehem, Pennsylvania, the Company has assembled a team of experienced medical scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.

For additional information please visit
Follow us on Twitter @Cerora1.

Contact Information